AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...
AstraZeneca PLC (NASDAQ:AZN) operates across global healthcare markets through advanced research pathways, biopharmaceutical ...
AstraZeneca secured U.S. approval for its IMFINZI (durvalumab) regimen in combination with FLOT chemotherapy for early-stage ...
Imfinzi is the first perioperative immunotherapy approved for resectable gastric/GEJ cancers, offering a new treatment ...
The U.S. Food and Drug Administration has approved Imfinzi (durvalumab) in combination with standard-of-care FLOT ...
FADU unveils Gen7 SSD and PMIC push to cut power, speed AI data access FADU targets 100 million IOPS and companion PMICs to cut data center power and latency ...
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
Cambridge: AstraZeneca has announced that its New Drug Application (NDA) for baxdrostat has been accepted for Priority Review ...
TipRanks on MSN
Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?
British drugmaker AstraZeneca ($AZN), fresh off a record-high stock price, continues to draw interest from U.S. and European ...
In today’s ACT Brief, we examine how the CRA role is transforming alongside modern clinical trial technology, review the ...
The FDA has approved durvalumab plus fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy as neoadjuvant and ...
AstraZeneca’s Imfinzi (durvalumab), in combination with standard of care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin and docetaxel), has been approved by the US FDA to treat adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback